vs

Side-by-side financial comparison of Applied Digital Corp. (APLD) and TransMedics Group, Inc. (TMDX). Click either name above to swap in a different company.

TransMedics Group, Inc. is the larger business by last-quarter revenue ($160.8M vs $126.6M, roughly 1.3× Applied Digital Corp.). TransMedics Group, Inc. runs the higher net margin — 65.6% vs -11.4%, a 77.0% gap on every dollar of revenue. On growth, Applied Digital Corp. posted the faster year-over-year revenue change (98.2% vs 32.2%). TransMedics Group, Inc. produced more free cash flow last quarter ($19.0M vs $-567.9M). Over the past eight quarters, Applied Digital Corp.'s revenue compounded faster (70.9% CAGR vs 28.8%).

BAE Systems Digital Intelligence is an international defence and security technology firm owned by BAE Systems. They specialize in delivering digital solutions that enable rapid, data-driven decision-making. Their services, solutions and products span customers in Law Enforcement, National Security, Government Departments and Government Enterprises, Critical National Infrastructure, Telecommunications, the Military, and Space.

TransMedics Group, Inc. develops and commercializes innovative medical technologies for organ transplantation. Its flagship Organ Care System keeps donor organs viable during transport, improving transplant outcomes for heart, lung, liver and kidney recipients. It serves transplant centers and organ procurement organizations across North America, Europe and Asia-Pacific.

APLD vs TMDX — Head-to-Head

Bigger by revenue
TMDX
TMDX
1.3× larger
TMDX
$160.8M
$126.6M
APLD
Growing faster (revenue YoY)
APLD
APLD
+66.0% gap
APLD
98.2%
32.2%
TMDX
Higher net margin
TMDX
TMDX
77.0% more per $
TMDX
65.6%
-11.4%
APLD
More free cash flow
TMDX
TMDX
$586.9M more FCF
TMDX
$19.0M
$-567.9M
APLD
Faster 2-yr revenue CAGR
APLD
APLD
Annualised
APLD
70.9%
28.8%
TMDX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
APLD
APLD
TMDX
TMDX
Revenue
$126.6M
$160.8M
Net Profit
$-14.4M
$105.4M
Gross Margin
20.6%
58.1%
Operating Margin
-24.5%
13.2%
Net Margin
-11.4%
65.6%
Revenue YoY
98.2%
32.2%
Net Profit YoY
89.6%
1436.9%
EPS (diluted)
$-0.07
$2.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APLD
APLD
TMDX
TMDX
Q4 25
$126.6M
$160.8M
Q3 25
$64.2M
$143.8M
Q2 25
$-33.3M
$157.4M
Q1 25
$52.9M
$143.5M
Q4 24
$63.9M
$121.6M
Q3 24
$60.7M
$108.8M
Q2 24
$43.7M
$114.3M
Q1 24
$43.3M
$96.8M
Net Profit
APLD
APLD
TMDX
TMDX
Q4 25
$-14.4M
$105.4M
Q3 25
$-16.9M
$24.3M
Q2 25
$-52.5M
$34.9M
Q1 25
$-35.6M
$25.7M
Q4 24
$-138.7M
$6.9M
Q3 24
$-4.2M
$4.2M
Q2 24
$-64.5M
$12.2M
Q1 24
$-62.8M
$12.2M
Gross Margin
APLD
APLD
TMDX
TMDX
Q4 25
20.6%
58.1%
Q3 25
13.4%
58.8%
Q2 25
61.4%
Q1 25
7.1%
61.5%
Q4 24
18.0%
59.2%
Q3 24
-0.6%
55.9%
Q2 24
-9.1%
60.6%
Q1 24
-8.6%
61.9%
Operating Margin
APLD
APLD
TMDX
TMDX
Q4 25
-24.5%
13.2%
Q3 25
-34.7%
16.2%
Q2 25
23.2%
Q1 25
-35.8%
19.1%
Q4 24
-29.1%
7.1%
Q3 24
15.6%
3.6%
Q2 24
-68.4%
10.9%
Q1 24
-128.8%
12.8%
Net Margin
APLD
APLD
TMDX
TMDX
Q4 25
-11.4%
65.6%
Q3 25
-26.4%
16.9%
Q2 25
157.8%
22.2%
Q1 25
-67.2%
17.9%
Q4 24
-217.2%
5.6%
Q3 24
-7.0%
3.9%
Q2 24
-147.5%
10.7%
Q1 24
-145.0%
12.6%
EPS (diluted)
APLD
APLD
TMDX
TMDX
Q4 25
$-0.07
$2.59
Q3 25
$-0.07
$0.66
Q2 25
$-0.31
$0.92
Q1 25
$-0.16
$0.70
Q4 24
$-0.66
$0.19
Q3 24
$-0.03
$0.12
Q2 24
$-0.57
$0.35
Q1 24
$-0.52
$0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APLD
APLD
TMDX
TMDX
Cash + ST InvestmentsLiquidity on hand
$1.9B
Total DebtLower is stronger
Stockholders' EquityBook value
$1.4B
$473.1M
Total Assets
$5.2B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APLD
APLD
TMDX
TMDX
Q4 25
$1.9B
Q3 25
$73.9M
Q2 25
$41.6M
Q1 25
$68.7M
Q4 24
$286.2M
Q3 24
$58.2M
$330.1M
Q2 24
$3.3M
$362.8M
Q1 24
$4.4M
$350.2M
Stockholders' Equity
APLD
APLD
TMDX
TMDX
Q4 25
$1.4B
$473.1M
Q3 25
$1.0B
$355.2M
Q2 25
$497.7M
$318.1M
Q1 25
$454.6M
$266.3M
Q4 24
$434.6M
$228.6M
Q3 24
$241.8M
$209.9M
Q2 24
$124.8M
$189.9M
Q1 24
$118.5M
$159.5M
Total Assets
APLD
APLD
TMDX
TMDX
Q4 25
$5.2B
$1.1B
Q3 25
$2.4B
$946.0M
Q2 25
$1.9B
$890.5M
Q1 25
$1.7B
$837.5M
Q4 24
$1.5B
$804.1M
Q3 24
$937.7M
$785.6M
Q2 24
$762.9M
$758.6M
Q1 24
$643.2M
$723.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APLD
APLD
TMDX
TMDX
Operating Cash FlowLast quarter
$-15.8M
$34.5M
Free Cash FlowOCF − Capex
$-567.9M
$19.0M
FCF MarginFCF / Revenue
-448.6%
11.8%
Capex IntensityCapex / Revenue
436.1%
9.7%
Cash ConversionOCF / Net Profit
0.33×
TTM Free Cash FlowTrailing 4 quarters
$-1.3B
$133.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APLD
APLD
TMDX
TMDX
Q4 25
$-15.8M
$34.5M
Q3 25
$-82.0M
$69.6M
Q2 25
$6.9M
$91.6M
Q1 25
$5.9M
$-2.9M
Q4 24
$-52.3M
$19.7M
Q3 24
$-75.9M
$6.9M
Q2 24
$-34.1M
$25.7M
Q1 24
$38.8M
$-3.4M
Free Cash Flow
APLD
APLD
TMDX
TMDX
Q4 25
$-567.9M
$19.0M
Q3 25
$-331.4M
$61.9M
Q2 25
$-191.4M
$82.5M
Q1 25
$-251.6M
$-29.9M
Q4 24
$-223.3M
$6.1M
Q3 24
$-130.7M
$-41.3M
Q2 24
$-88.9M
$2.0M
Q1 24
$-2.3M
$-47.6M
FCF Margin
APLD
APLD
TMDX
TMDX
Q4 25
-448.6%
11.8%
Q3 25
-516.1%
43.1%
Q2 25
574.8%
52.4%
Q1 25
-475.4%
-20.8%
Q4 24
-349.6%
5.0%
Q3 24
-215.3%
-38.0%
Q2 24
-203.5%
1.7%
Q1 24
-5.4%
-49.2%
Capex Intensity
APLD
APLD
TMDX
TMDX
Q4 25
436.1%
9.7%
Q3 25
388.4%
5.3%
Q2 25
-595.4%
5.8%
Q1 25
486.6%
18.8%
Q4 24
267.8%
11.2%
Q3 24
90.3%
44.3%
Q2 24
125.4%
20.8%
Q1 24
95.0%
45.6%
Cash Conversion
APLD
APLD
TMDX
TMDX
Q4 25
0.33×
Q3 25
2.86×
Q2 25
2.62×
Q1 25
-0.11×
Q4 24
2.87×
Q3 24
1.63×
Q2 24
2.11×
Q1 24
-0.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

APLD
APLD

HPC Hosting Business$85.0M67%
Data Center Hosting Business$41.6M33%

TMDX
TMDX

Liver Product$127.0M79%
Heart Product$26.0M16%
Other$5.9M4%
Lung Product$1.9M1%

Related Comparisons